Hikmet, Rawan http://orcid.org/0000-0002-1059-5672
Harsløf, Torben http://orcid.org/0000-0002-8581-3523
Langdahl, Bente Lomholt http://orcid.org/0000-0002-8712-7199
Funding for this research was provided by:
Pharmaprim and EffRx (37.100 euro)
Aarhus University Hospital
Article History
Received: 2 June 2023
Accepted: 5 September 2023
First Online: 6 October 2023
Declarations
:
: Torben Harsløf received lecture fees from Amgen, Astra Zeneca, and Eli Lilly and lecture fees and travel grants from UCB. Bente Lomholt Langdahl has received research funding to her institution from Amgen and Novo Nordisk. Bente Lomholt Langdahl serves on advisory boards and speaker’s bureau for Amgen, UCB, Gilead, and Gedeon-Richter. Rawan Hikmet has no conflicts of interest to declare.
: This study was conducted according to the Helsinki Declaration, the Danish Health Law, and GCP guidelines. The Danish Data Protection Agency, The Regional Ethics Committee and The Danish Health and Medicine Authority approved the study. The local Good Clinical Practice (GCP) at Aalborg and Aarhus University Hospital monitored the trial. Written informed consent was obtained from all participants included in this study before any procedures were performed.